BIO-TECHNE Corp (TECH)
Biological Products, (No Diagnostic Substances)
Latest Price
$72.09
TTM P/E
104.48
Normalized P/E
32.00
Div Yield
0.44%
Book Value
13.38
P/B Ratio
5.39
Valuation metrics
adjust assumptions →EPS: $0.46
Book value / share: $13.35
Formula: √(22.5 × EPS × BVPS)
Graham Number
$11.75
84% downside
Norm. op. income: $207M (median of 7yr)
Tax rate: 14%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$10.26
86% downside
Base FCF: $257M (median of recent 5yr)
Growth: 3%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$24.01
67% downside
EPS: $0.46
Target P/E: 32×
Formula: EPS × P/E
P/E Fair Value
$14.72
80% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12.26M | $640.0M | 7.84% | +135.4K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.18M | $531.0M | 6.50% | -- | 2026-03-31 |
| MORGAN STANLEY | 8.53M | $445.0M | 5.45% | +187.5K | 2026-03-31 |
| FMR LLC | 7.90M | $412.0M | 5.05% | +6.88M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.48M | $338.0M | 4.14% | -- | 2026-03-31 |
| STATE STREET CORP | 5.87M | $306.0M | 3.75% | +56.4K | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.12M | $267.0M | 3.27% | -613.9K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 5.11M | $266.0M | 3.27% | +182.6K | 2026-03-31 |
| MAVERICK CAPITAL LTD | 4.74M | $247.0M | 3.03% | +888.8K | 2026-03-31 |
| Invesco Ltd. | 4.59M | $239.0M | 2.93% | +910.0K | 2026-03-31 |